We are pleased to inform you that we had received a milestone payment from Aligos Therapeutics, Inc. in connection with a development milestone event specified in the technology license agreement which was entered into during December 2018 between Luxna Biotech and Aligos Therapeutcs fort he use of our  innovative modified nucleic acid technology.

Please check here for details.